<DOC>
	<DOCNO>NCT01286701</DOCNO>
	<brief_summary>The purpose study compare rate extent absorption terbinafine hydrochloride 250 mg tablet versus Lamisil® 250 mg tablet administer 1 x 250 mg tablet feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Terbinafine Hydrochloride Tablets , 250 mg Dr. Reddy 's Under Fed Conditions</brief_title>
	<detailed_description>Randomized , 2-way crossover , bioequivalence study Terbinafine hydrochloride 250 mg tablet Lamisil® 250 mg Tablets administer 1 x 250 mg tablet healthy subject feed condition .</detailed_description>
	<mesh_term>Terbinafine</mesh_term>
	<criteria>Subjects enrol study member community large . The recruitment advertisement may do use different medium ( e.g . radio , newspaper , Anapharm Web site , Anapharm volunteer ' data base ) . Subjects must meet follow criterion order include study : Subjects females and/or male , smoker and/or nonsmoker , 18 year age old . Subjects follow applies exclude study : Clinically significant illness within 4 week administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion medical subinvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mm Hg ; heart rate le 50 bpm ) screening . Subjects BMI ≥ 30.0 . History significant alcohol abuse within six month screen visit indication regular use two unit alcohol per day ( 1 Unit = 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit . Any food allergy , intolerance , restriction special diet , opinion medical subinvestigator , contraindicate subject participation study . History allergic reaction terbinafine hydrochloride relate drug ( e.g.naftifine ) . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) , use investigational drug participation investigational study within 30 day prior administration study medication . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural product , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption oral contraceptive . Subjects depot injection implant drug ( except depot injection implant use method contraception ) 3 month prior administration study medication . Subjects history previous liver disease . Donation plasma ( 500 mL ) within 7 day . Donation loss whole blood prior administration study medication follow : le 300 mL whole blood within 30 day 300 mL 500 mL whole blood within 45 day 500 mL whole blood within 56 day . •Smoking 25 cigarette per day . Additional exclusion criterion female : Breastfeeding subject . Positive urine pregnancy test screening ( performed female ) . Female subject childbearing potential unprotected sexual intercourse nonsterile male partner ( i.e . male sterilized vasectomy least 6 month ) within 14 day prior study drug administration . The acceptable method contraception : Condom + spermicide Diaphragm + spermicide Intrauterine contraceptive device ( place least 4 week prior study drug administration ) oral contraceptive ( start least 4 week prior study drug administration ) Implant ( e.g . Norplant® ) ( start least 4 week prior study drug administration ) Depot injection progestogen drug ( e.g . DepoProvera® ) ( start least 4 week prior study drug administration )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>crossover</keyword>
	<keyword>Terbinafine hydrochloride</keyword>
	<keyword>fed</keyword>
</DOC>